Clinical Trial Update: Assessment of Onset, Safety & Toleration of UK-369,003 in Male Erectile Dysfunction [Phase 2]

View source ↗

Summary

Phase 2 study evaluating onset, safety, and tolerability of Pfizer's UK-369,003 in men with erectile dysfunction; the trial is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erectile Dysfunction

Drugs mentioned

• UK-369,003 (UK-369,003)

Snippet

Sponsor: Pfizer | Conditions: Impotence | Phase 2 | Status: COMPLETED